NDR1 Activators
NDR1 activators represent a class of chemicals selected for their potential to modulate the activity of NDR1, a protein pivotal in cellular processes such as cell cycle regulation and apoptosis. While direct activators may not be explicitly identified, these chemicals exert their effects through indirect mechanisms, primarily by targeting key kinases and pathways associated with NDR1 regulation. Staurosporine, a broad-spectrum protein kinase inhibitor, impacts various signaling pathways, potentially influencing the phosphorylation events associated with NDR1 activation. Similarly, H-89, a selective inhibitor of protein kinase A (PKA), indirectly modulates NDR1 by disrupting PKA-dependent events, altering the regulatory mechanisms governing NDR1 in cell cycle progression and cytoskeletal dynamics. Bisindolylmaleimide I and Gö 6976, selective inhibitors of protein kinase C (PKC), can indirectly activate NDR1 by disrupting PKC-dependent events, affecting downstream signaling cascades related to cell cycle regulation and cell motility.
LY333531, a specific inhibitor of PKCβ, and Indirubin-3'-monoxime, a CDK inhibitor, further exemplify the indirect activation of NDR1. These chemicals disrupt specific kinase activities associated with NDR1 pathways, potentially altering its role in cellular processes related to cell cycle progression and apoptosis. SP600125, a JNK inhibitor, and Bisindolylmaleimide II, another PKC inhibitor, indirectly influence NDR1 activation through modulation of downstream kinase-dependent events, illustrating the interconnectedness of signaling cascades governing NDR1. The class also includes TGX-221, a PI3K inhibitor, AZD7762, a CHK1 inhibitor, SB 203580, a p38 MAPK inhibitor, and Purvalanol A, a CDK inhibitor. These chemicals impact various cellular processes by indirectly influencing NDR1 activation through disruption of specific kinase-dependent events.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. By targeting various kinases, including those involved in cellular signaling pathways, staurosporine can indirectly modulate the activation of NDR1. This inhibition affects multiple pathways, potentially impacting the phosphorylation events associated with NDR1 activation and its subsequent involvement in cellular processes related to cell cycle regulation and apoptosis. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $103.00 $237.00 | 36 | |
Bisindolylmaleimide I is a general protein kinase C (PKC) inhibitor. Since PKC plays a role in cellular signaling pathways involving NDR1, this inhibitor can indirectly affect the activation of NDR1 by disrupting PKC-dependent events. The altered activity of PKC can impact NDR1-associated functions, potentially leading to its activation in response to changes in PKC-mediated signaling cascades, especially those related to cell cycle regulation and cell motility. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $223.00 | 8 | |
Gö 6976 is a selective inhibitor of protein kinase C (PKC) that can impact cellular signaling pathways involving NDR1. By inhibiting PKC, Gö 6976 may indirectly activate NDR1 through modulation of downstream PKC-dependent events. The altered activity of PKC can influence NDR1-associated functions, possibly leading to its activation in response to changes in PKC-mediated signaling cascades, particularly those related to cell cycle regulation and cytoskeletal dynamics. | ||||||
LY-333,531 Hydrochloride | 169939-93-9 | sc-364215 sc-364215A | 1 mg 5 mg | $92.00 $281.00 | 6 | |
LY333531 is a specific inhibitor of protein kinase C beta (PKCβ), a kinase involved in various cellular processes, including those associated with NDR1 regulation. By inhibiting PKCβ, LY333531 can indirectly modulate the activation of NDR1, impacting downstream signaling events. | ||||||
Indirubin-3′-monoxime | 160807-49-8 | sc-202660 sc-202660A sc-202660B | 1 mg 5 mg 50 mg | $77.00 $315.00 $658.00 | 1 | |
Indirubin-3'-monoxime is a selective inhibitor of cyclin-dependent kinases (CDKs), which are involved in cell cycle regulation. By inhibiting CDKs, including those associated with NDR1 pathways, indirubin-3'-monoxime can indirectly influence the activation of NDR1. This inhibition affects the phosphorylation events associated with NDR1 activation, potentially altering its role in cellular processes related to cell cycle progression and apoptosis. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $65.00 $267.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK), a kinase implicated in cellular signaling pathways involving NDR1. By inhibiting JNK, SP600125 may indirectly activate NDR1 through modulation of downstream JNK-dependent events. The altered activity of JNK can influence NDR1-associated functions, possibly leading to its activation in response to changes in JNK-mediated signaling cascades, particularly those related to cell cycle regulation and apoptosis. | ||||||
PI 3-Kβ Inhibitor VI, TGX-221 | 663619-89-4 | sc-203190 | 1 mg | $437.00 | ||
TGX-221 is a selective inhibitor of phosphoinositide 3-kinase (PI3K), a kinase involved in various cellular processes, including those associated with NDR1 regulation. By inhibiting PI3K, TGX-221 can indirectly modulate the activation of NDR1, impacting downstream signaling events. | ||||||
AZD7762 | 860352-01-8 | sc-364423 | 2 mg | $107.00 | ||
AZD7762 is a selective inhibitor of checkpoint kinase 1 (CHK1), a kinase involved in cell cycle regulation. By inhibiting CHK1, AZD7762 can indirectly influence the activation of NDR1. This inhibition affects the phosphorylation events associated with NDR1 activation, potentially altering its role in cellular processes related to cell cycle progression and apoptosis. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB 203580 is a selective inhibitor of p38 mitogen-activated protein kinase (MAPK), a kinase implicated in cellular signaling pathways involving NDR1. By inhibiting p38 MAPK, SB 203580 may indirectly activate NDR1 through modulation of downstream p38 MAPK-dependent events. | ||||||
Purvalanol A | 212844-53-6 | sc-224244 sc-224244A | 1 mg 5 mg | $71.00 $291.00 | 4 | |
Purvalanol A is a selective inhibitor of cyclin-dependent kinases (CDKs), including those associated with NDR1 pathways. By inhibiting CDKs, Purvalanol A can indirectly influence the activation of NDR1. This inhibition affects the phosphorylation events associated with NDR1 activation, potentially altering its role in cellular processes related to cell cycle progression and apoptosis. | ||||||